NCT01653574已完成2 期
A Single-Institutional, Phase II, Open-label, Single Arm Trial of Famitinib Malate in in HER2-negative Metastatic Breast Cancer
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 28
- 试验地点
- 1
- 主要终点
- ORR (Objective response rate)
研究概览
简要总结
The hypothesis of this clinical research study is to discover if the study drug Famitinib Malate can shrink or slow the growth of pretreated HER2-negative metastatic breast cancer.
详细描述
Famitinib Malate is a tyrosine kinase inhibitor mainly targeting vascular endothelial growth factor receptor 2(VEGFR2), and its anti-angiogenesis effect has been viewed in preclinical tests. The investigators' phase I study has shown that the drug's toxicity is manageable and the recommended phase II dose is 25 mg. The hypothesis of this clinical research study is to discover if the study drug Famitinib Malate can shrink or slow the growth of pretreated HER2-negative breast cancer. The safety of Famitinib Malate will also be studied. Patients physical state, symptoms, changes in the size of the tumor, and laboratory findings obtained while on-study will help the research team decide if Famitinib Malate is safe and effective in pretreated HER2-negative metastatic breast cancer patients.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- Female
- 接受健康志愿者
- 否
入选标准
- •●≥ 18 and ≤ 70 years of age.
- •ECOG performance status of 0-
- •Women diagnosed with HER2-negative breast cancer. HER2- is defined as 0 or 1+ staining on immunohistochemistry or FISH/CISH negative for gene amplification.
- •Metastatic breast cancer, confirmed by histological analysis.
- •Have failed from the last chemotherapy regimen, but experienced at most 2 regimens in the relapsed or metastatic setting. Pretreated anthracycline, taxanes and capecitabine (any rational reason for no use of capecitabine is acceptable) are mandatory.
- •Have failed from at least 1 endocrine therapy, if HR positive.
- •Duration from the last therapy (chemotherapy, radiotherapy, target therapy and operation) is more than 4 weeks (Duration for nitroso or mitomycin is 6 weeks).
- •Have at least one extracranial measurable site of disease according to RECIST 1.1 criteria that has not been previously irradiated.
- •Life expectancy of more than 3 months.
- •If the patients have brain or meninges metastases, the lesions must have been controlled at least 8 weeks.
- •Adequate hepatic, renal, heart, and hematologic functions (hemoglobin ≥ 90g/L, neutrophils ≥ 1.5×10^9/L, platelets ≥ 80×10^9/L , ALT ≤ 2.5 x upper limit of normal (ULN), AST ≤ 2.5 x ULN, serum bilirubin ≤ 1.5 x ULN, serum creatine ≤ 1.5 x ULN, creatinine clearance rate ≥ 50ml/min, PT, APTT ≤ 1.5 x ULN), serum cholesterol ≤ 1.25 x ULN, serum glycerin trilaurate ≤ 2.0 x ULN, LVEF ≥ lower limit of normal (LLN).
- •Negative serum or urine pregnancy test taken in all women within 7 days before inclusion. Sexually active women of childbearing potential must use a medically acceptable form of contraception (which include oral contraception, injectable or implantable methods, intrauterine devices, or properly used barrier contraception) from the beginning of the study to 8 weeks after the last dose of the investigated drug. A woman of childbearing potential is defined as one who is biologically capable of becoming pregnant. This includes women who are using contraceptives or whose sexual partners are either sterile or using contraceptives.
- •Written informed consent prior to study specific screening procedures, with the understanding that the patient has the right to withdraw from the study at any time without prejudice.
排除标准
- •Pregnant or lactating women.
- •Uncontrolled hypertension with mono-drug therapy (>140/90 mm Hg)；ischemia of the myocardium （≥ grade 2） or myocardial infarction；arrhythmia（≥ grade 2, QTcF > 480ms for female patients） or New York Heart Association Class III/IV.
- •Abnormal thyroid function history with drug intervention.
- •Any factors that influence the usage of oral administration.
- •The cumulative doses of doxorubicin and epirubicin before inclusion have surpassed 300 mg/m2 and 600 mg/m2, respectively.
- •Brain or meningeal metastases.
- •Receiving the therapy of thrombolysis or anticoagulation.
- •Unhealed wound or bone fracture.
- •Urine protein ≥++ and confirmed >1.0 g by the 24h quantity.
- •Previous or present history of pulmonary fibrosis,interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonitis or greatly-impaired pulmonary function.
- •Disability of serious uncontrolled intercurrence infection.
- •The active HBV or HCV infection or HBV DNA ≥10^4/ml.
- •Acquired or inherent immunodeficiency； HIV infection； organ transplantation history.
- •Abuse of alcohol or drugs.
- •Have received prior treatment with a VEGFR TKI (Bevacizumab is permitted).
- •History of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix.
研究组 & 干预措施
Famitinib Malate
Experimental
Famitinib 25mg/d
干预措施: Famitinib Malate (Drug)
结局指标
主要结局
ORR (Objective response rate)
时间窗: 8 Weeks
次要结局
- QoL (Quality of life)(8 Weeks)
- PFS(Progression free survival)(8 Weeks)
- OS (Overall survival)(8 Weeks)
- CBR(Clinical benefit rate)(8 Weeks)
- Number of adverse events(8 Weeks)
研究者
Xichun Hu
Deputy director of department of medical oncology
Fudan University
研究点 (1)
Loading locations...
相似试验
Unknown
2 期
A Study of Famitinib in Combination With HS-10296 in Patients With EGFR-mutant NSCLCEGFR-mutant Non-Small Cell Lung CancerNCT03904823Jiangsu HengRui Medicine Co., Ltd.58
终止
2 期
Safety and Efficacy of Pemigatinib in Patients With High-risk Urothelial Cancer After Radical SurgeryUrothelial CancerNCT04294277European Association of Urology Research Foundation2
已完成
2 期
Safety and Efficacy of Imatinib Added to Chemotherapy in Treatment of Ph+ Acute Lymphoblastic Leukemia in ChildrenPhiladelphia ChromosomeAcute Lymphoblastic LeukemiaNCT00287105Rennes University Hospital49
终止
3 期
Efficacy and Safety of Famitinib Versus Sunitinib in the Treatment of Advanced Gastrointestinal Stromal Tumour Patients After Failure of ImatinibGastrointestinal Stromal TumorsNCT04409223Jiangsu HengRui Medicine Co., Ltd.185
尚未招募
2 期
Sintilimab (One Anti-PD-1 Antibody) Plus Low-dose Bevacizumab for ctDNAlevel- Relapse and Clinical-relapse AstrocytomaAstrocytoma of BrainNCT05518994Henan Provincial People's Hospital70